There are currently 298 active clinical trials seeking participants for Prostate Cancer research studies. The states with the highest number of trials for Prostate Cancer participants are California, New York, Texas and Ohio.
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
NCT05804318
Recruiting
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Duarte Cancer Center, Duarte, California +4 locations
Conditions: Prostate Cancer
Register for Updates
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194
Recruiting
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Sarah Cannon Research Institute, Denver, Colorado +5 locations
Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer
Register for Updates
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT04486755
Recruiting
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Maryland Proton Treatment Center, Baltimore, Maryland
Conditions: Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
NCT06392295
Recruiting
The purpose of this prostate cancer research study is to learn about: 1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy; 2. Preserving quality of life after radiation therapy; 3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) scans to evaluate and manage disease progression.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/13/2025
Locations: University of Miami, Miami, Florida
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Register for Updates
High Intensity Focused Ultrasound in Prostate Cancer
NCT06402357
Recruiting
This study will investigate the efficacy of focal high intensity focused ultrasound (HIFU) in patients with localized radiorecurrent prostate cancer. This study will also investigate the change in participant quality of life after HIFU therapy as compared to before HIFU therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Prostate Cancer
Register for Updates
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
NCT05790213
Recruiting
The purpose of this research is to gather information on the safety and effectiveness of combining focal prostate ablation therapy ((aka Focal Therapy, a surgical procedure) and androgen deprivation therapy (hormone therapy).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: UChicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697
Recruiting
This study is being done to answer the following question: Is the strategy to give higher doses of radiotherapy treatment over a shorter period of time using special equipment and fewer treatments (also known as Stereotactic Body Radiation Therapy or SBRT) as effective as usual external radiation therapy given with a brachytherapy boost (which involves radiation sources inserted directly into the prostate)?
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri +12 locations
Conditions: Prostate Cancer
Register for Updates
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT03769766
Recruiting
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Gender:
MALE
Ages:
Between 40 years and 89 years
Trial Updated:
06/06/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
Geriatric Assessment and Technology Evaluation in Prostate Cancer
NCT06215508
Recruiting
By doing this study, doctors hope to learn more about factors that contribute to frailty (a condition where older adults feel weak, get tired easily, and struggle more with everyday activities) and serious side effects among men over the age of 65 who will receive androgen deprivation therapy (also called "hormone therapy") for prostate cancer that has spread to other parts of their body. Participation in this research will last about 5 years. For the first year, participants will have 5 study v... Read More
Gender:
MALE
Ages:
18 minutes and above
Trial Updated:
06/06/2025
Locations: o University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Prostate Cancer, Prostate Cancer Metastatic
Register for Updates
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
NCT06824818
Recruiting
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Gender:
MALE
Ages:
70 years and above
Trial Updated:
06/06/2025
Locations: The University of Illinois at Chicago (UIC), Chicago, Illinois +1 locations
Conditions: Elderly, Prostate Cancer
Register for Updates
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT04221542
Recruiting
Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Part 2 is now closed to accrual.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: City of Hope National Medical Center, Duarte, California +53 locations
Conditions: Prostate Cancer
Register for Updates
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05011188
Recruiting
This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abiraterone. FOR46 is designed to target and bind to CD46, a transmembrane cellular protein expressed at moderate or high levels in numerous cancer types. The investigators hypothesize that the combination of FOR46 plus enzalutamide will achieve a clinically significant composite response rate with sufficient durability o... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/05/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Register for Updates